Project Grant K08HL171843
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$168K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,057,973 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Johns Hopkins University to conduct research on modeling fetal lung development in congenital diaphragmatic hernia (CDH). The research aims to investigate the role of the YAP/TAZ mechanosensing pathway in CDH lung hypoplasia using mouse models, human lung organoids, and large animal fetal models. The research teams led by Shaun Kunisaki, Jason...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $812,189 to Brigham & Women's Hospital Inc. for a research project titled "Clinical CT Imaging for Screening and Subtyping of Pulmonary Hypertension in COPD". The project aims to leverage CT imaging data from several NIH-funded cohorts, including PVDOMICS, COPDGENE, and CARDIA, to develop non-invasive methods for diagnosing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $750,162 to The Children's Hospital of Philadelphia (CHOP) to conduct research aimed at understanding the role of lymphatic dysfunction in the development of post-lung transplant bronchiolitis obliterans syndrome (BOS), a serious complication. The research project will use murine models to investigate the mechanisms of lymphatic vascular function after...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $123,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Chicago to investigate the role of the Hedgehog (HH) signaling pathway in regulating progenitor cell differentiation during lung development and disease. The 2-year grant, which runs from February 2025 to November 2026, aims to: 1) decipher HH's temporal control over differentiation in mouse lungs, 2) characterize HH-receiving cell...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $865,694 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) from June 2025 to April 2029. The award aims to investigate the role of the neuropilin-2 (NRP2) receptor in regulating lymphatic function and lipid absorption, with the goal of developing novel treatments for lymphedema and obesity....